Should a urine culture growing 10,000–25,000 CFU/mL Enterococcus faecalis be treated as a urinary tract infection, and what is the appropriate antimicrobial regimen?

Should 10,000-25,000 CFU/mL Enterococcus faecalis Be Treated?

Do not automatically treat urine cultures growing 10,000-25,000 CFU/mL Enterococcus faecalis—treatment depends entirely on whether the patient has urinary symptoms, and the traditional 100,000 CFU/mL threshold does not apply to enterococcal infections.

Clinical Decision Framework

Step 1: Determine if Symptoms Are Present

The most critical distinction is between asymptomatic bacteriuria (ABU) and true urinary tract infection:

• If asymptomatic: Do not treat 1. The 2024 EAU guidelines strongly recommend against screening for or treating ABU in most populations, as treatment risks selecting for antimicrobial resistance and eradicating potentially protective bacterial strains.

• If symptomatic: Proceed to treatment evaluation. Research demonstrates that more than half of patients with enterococcal counts between 10,000-100,000 CFU/mL have true UTI, especially when hospitalized or experiencing dysuria, urgency, or frequency 2. The enterococcal counts are randomly distributed across this range with no differential cutoff—meaning 10,000 CFU/mL can be just as clinically significant as 50,000 CFU/mL.

Step 2: Assess for Complicating Factors

Enterococcus faecalis UTI should be classified as complicated or uncomplicated 1:

Complicated UTI indicators include:

• Male sex
• Indwelling urinary catheter (strongest predictor, OR 2.05) 3
• Recent urinary instrumentation (OR 2.16) 3
• Pregnancy
• Diabetes mellitus
• Immunosuppression
• Obstruction or incomplete voiding
• Recent healthcare exposure

Key clinical pitfall: E. faecalis is particularly common in hospitalized patients with urinary catheters and recent antibiotic exposure 4. These patients warrant empiric anti-enterococcal coverage even before culture results.

Step 3: Verify Leukocyturia

Only treat if both bacteriuria AND leukocyturia are present 2. The combination confirms true infection rather than colonization. Without pyuria, even symptomatic patients may have alternative diagnoses.

Treatment Regimens

For Uncomplicated E. faecalis UTI (Susceptible Strains)

First-line: Ampicillin

• Ampicillin is the drug of choice for enterococcal infections 5, 6
• Dosing: High-dose ampicillin 18-30g IV daily OR amoxicillin 500mg PO/IV every 8 hours 5
• Duration: 7 days for women, 14 days for men (when prostatitis cannot be excluded) 1

Alternative options:

• Nitrofurantoin: 100mg twice daily for 5 days (lower UTI only) 1, 7
• Fosfomycin: 3g single dose (FDA-approved specifically for E. faecalis UTI) 5, 7
• Fluoroquinolones: Only if susceptible and local resistance <10% 1

For Complicated E. faecalis UTI

Empiric therapy 1:

• Amoxicillin plus aminoglycoside, OR
• Second-generation cephalosporin plus aminoglycoside, OR
• Third-generation cephalosporin IV

Duration: 7-14 days depending on clinical response and underlying abnormality correction 1

For Ampicillin-Resistant or Vancomycin-Resistant E. faecalis

Treatment options 5, 7:

• Daptomycin: 8-12 mg/kg IV daily (preferred for serious infections due to bactericidal activity)
• Linezolid: 600mg twice daily
• Tigecycline: For intra-abdominal sources only (achieves poor serum levels, avoid for bacteremia)

Critical consideration: High urinary concentrations of ampicillin may overcome resistance in UTI specifically—one study showed 88.1% clinical success treating ampicillin-resistant VRE UTI with ampicillin 5. Consider high-dose ampicillin even for resistant strains in isolated UTI.

Special Populations

Pregnant Women

Screen for and treat ABU in pregnancy with standard short-course treatment or single-dose fosfomycin 1. This is the only population where treating asymptomatic enterococcal bacteriuria is recommended.

Catheterized Patients

• Do not treat catheter-associated ABU 1, 8
• Remove or replace catheter when feasible 7
• Only treat if symptomatic with fever, rigors, altered mental status, flank pain, or suprapubic pain 1

Before Urologic Procedures

Screen for and treat ABU before endoscopic procedures with mucosal trauma 8. Use 1-2 doses of targeted antimicrobial therapy 30-60 minutes before the procedure.

Common Pitfalls to Avoid

1. Do not reflexively treat low colony counts as contamination: Microbiology laboratories should perform complete workup on samples with 10,000-25,000 CFU/mL enterococci, as these frequently represent true infection 2

2. Do not use cephalosporins alone for enterococcal coverage: Enterococci have intrinsic resistance to cephalosporins 6

3. Do not treat polymicrobial cultures with enterococci automatically: Consider contamination or colonization, especially with >2 organisms 9, 10

4. Do not use tigecycline for enterococcal bacteremia: Large volume of distribution results in inadequate serum levels 5

5. Recognize that inadequate empiric therapy is common: 66.6% of E. faecalis UTI patients receive inadequate initial antibiotics compared to 19% with gram-negative UTI 3